{
    "2019-09-23": [
        [
            {
                "time": "",
                "original_text": "抢占下一代药王先机？市值270亿的君实生物资本疾行",
                "features": {
                    "keywords": [
                        "药王",
                        "市值",
                        "君实生物",
                        "资本"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "302家医疗上市公司，3家营收超30亿元！",
                "features": {
                    "keywords": [
                        "医疗",
                        "上市公司",
                        "营收"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-16至2019-09-22",
                "original_text": "消费+科技属性将驱动医药长牛 —— 医药行业周报（2019.09.16-2019.09.22）",
                "features": {
                    "keywords": [
                        "消费",
                        "科技",
                        "医药",
                        "长牛"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【中信建投医药|行业周报】新旧交替机会不断 配置高性价比标的",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药",
                        "新旧交替",
                        "高性价比"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}